Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

4.170 -0.030 (-0.71%)
Streaming Delayed Price Updated: 3:46 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 247,285
Open 4.210
Bid (Size) 4.160 (100)
Ask (Size) 4.180 (200)
Prev. Close 4.200
Today's Range 4.070 - 4.250
52wk Range 3.270 - 7.610
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence

Performance

YTD
-19.7%
-19.7%
1 Month
-38.2%
-38.2%
3 Month
+0.5%
+0.5%
6 Month
-14.7%
-14.7%
1 Year
-13.1%
-13.1%

More News

Read More
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Via Investor Brand Network
News headline image
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
Via Benzinga
News headline image
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Foghorn Therapeutics Inc. - Common Stock publicly traded?
Yes, Foghorn Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Foghorn Therapeutics Inc. - Common Stock trade on?
Foghorn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Foghorn Therapeutics Inc. - Common Stock?
The ticker symbol for Foghorn Therapeutics Inc. - Common Stock is FHTX on the Nasdaq Stock Market
What is the current price of Foghorn Therapeutics Inc. - Common Stock?
The current price of Foghorn Therapeutics Inc. - Common Stock is 4.170
When was Foghorn Therapeutics Inc. - Common Stock last traded?
The last trade of Foghorn Therapeutics Inc. - Common Stock was at 09/18/26 03:46 PM ET
What is the market capitalization of Foghorn Therapeutics Inc. - Common Stock?
The market capitalization of Foghorn Therapeutics Inc. - Common Stock is 154.03M
How many shares of Foghorn Therapeutics Inc. - Common Stock are outstanding?
Foghorn Therapeutics Inc. - Common Stock has 154M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.